Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is currently conducting a clinical study titled ‘XALKORI ROS1+NSCLC DRUG USE INVESTIGATION’ to evaluate the safety and efficacy of Xalkori (crizotinib) in patients with non-small cell lung cancer (NSCLC). The study aims to gather data on unexpected adverse drug reactions, the incidence of these reactions, and factors influencing the drug’s safety and efficacy.
The intervention being tested is crizotinib, marketed as XALKORI®, which is administered in capsule form. The recommended dosage is 250 mg taken orally twice daily, with adjustments based on patient response.
This observational study follows a case-only model with a prospective time perspective. It does not involve allocation or masking, focusing solely on collecting observational data to assess the drug’s impact.
The study began on December 12, 2017, and is currently recruiting participants. The primary completion date is not specified, but the last update was submitted on June 20, 2025. These dates are crucial for tracking the study’s progress and potential market entry timelines.
The study’s findings could significantly impact Pfizer’s stock performance by influencing investor sentiment, particularly if the results demonstrate enhanced safety and efficacy of Xalkori. This could also affect the competitive landscape in the NSCLC treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.